Juni 2022: Ucwaningo oluncane lweziguli ezinomdlavuza wama-rectal luveze imiphumela emangalisayo: amaphesenti ayi-100 abantu ayexolelwe. Imiphumela yashicilelwa ku-New England Journal of Medicine kuleli sonto.
Ukuqulwa kwecala bekuxhaswe i-GlaxoSmithKline, ekhiqize umuthi i-dostarlimab, ngokusho kwe-New York Times. Izinyanga eziyisithupha, iziguli ocwaningweni zanikezwa i-dostarlimab, i- immunotherapy umuthi oshukumisa amasosha omzimba eziguli ukuthi aqondise izifo ezibulalayo.
According to the study, all 12 people had comparable mutations in mismatch repair-deficient umdlavuza colorectal, which occurs in roughly 5 to 10% of colorectal malignancies. Standard chemotherapy has a dismal prognosis for these malignancies.
"Abanalo isakhi sofuzo esibavumela ukuthi balungise i-DNA yabo," udokotela u-Andrea Cercek, ongumdidiyeli walolu cwaningo ovela esikhungweni se-Memorial Sloan Kettering Disease Center, utshele i-CNN. "Ngenxa yalokho, banezinguquko eziningi, futhi amasosha omzimba abona umdlavuza njengowangaphandle." "Lapho sisebenzisa i-immunotherapy, njenge-dostarlimab, empeleni sivuselela amasosha omzimba ukuze abone umdlavuza futhi awubulale."
Dostarlimab is an antibody that targets the protein PD-1, which stands for programmed cell death 1. PD-1 is a protein found on the surface of immune system T-cells that helps the body recognise and destroy cancer cells. Cancer cells can then create chemicals that disrupt PD-1, allowing them to slip past the immune system’s detection. Dostarlimab works by preventing cancer cells from evading the immune system, allowing the immune system to discover and kill cancer cells. The researchers intended to follow up on the dostarlimab treatment with normal chemoradiotherapy and surgery, but the patients didn’t require it. According to the study, all 12 subjects who completed the dostarlimab treatment and had a 6-month follow-up had no detected cancer cells or major side effects. According to a statement, no cases of advancement or recurrence have been observed even after 25 months.
Traditional umdlavuza colon therapies can have life-changing consequences, according to Hanna Sanoff of the University of North Carolina’s Lineberger Comprehensive Cancer Center, who was not involved in the study but wrote an editorial about it.
“Both surgery and radiation have long-term implications for fertility, sexual health, and bowel and bladder function. “The consequences for quality of life are significant, particularly for women whose reproductive potential would be harmed by current treatment,” Cercek said in the statement. “With the increased incidence of rectal cancer among young persons, this method could have a significant impact.”
Ochwepheshe baxwayisa ngokuthi ukuhlola bekunomkhawulo, futhi kusesekuseni kakhulu ukuthi ungasho ukuthi iziguli zizoqhubeka yini nokuxolelwa. U-Sanoff uyanezela esihlokweni sokuhlela ukuthi ngisho nabantu abaye basabela ngokuphelele emisebeni ye-radiation kanye nokwelashwa ngamakhemikhali bangakwazi ukuphinde babe nomdlavuza emaphesentini angama-20 kuye kwangama-30 ezimeni lapho ubulwelwe busingathwa ngokungasebenzi.
I-PD-1 ihileleke endleleni enkulu yebhayoloji eyaziwa ngokuthi “i-checkpoint inhibition,” esebenza njengokuvula/ukuvala amaseli omzimba. Enye yezindawo ezisebenza kakhulu zokufunda ku-oncology njengamanje igxile ku-PD-1 nezinye izici zokuvimbela indawo yokuhlola ekwelashweni komdlavuza.
"Lokhu okutholakele kuyizizathu zokuba nethemba elikhulu," kusho uSanoff, "kodwa indlela enjalo ayikwazi ukudlula indlela yethu yokwelapha ekhona manje." Ucwaningo kufanele luphindwe, uyengeza.
Utshela i-NPR, “Engingathanda ngempela ukuba sikwenze ukuthola isivivinyo esibanzi lapho lo muthi usetshenziswa kubantu abahlukahlukene kakhulu ukuthola ukuthi lizoba yini izinga langempela lokuphendula eliyiqiniso.” “Ngeke kube ngamaphesenti ayikhulu.” Ngiyethemba ukuthi ngizokwazi ukubamba ulimi lwami kulokho esikhathini esizayo, kodwa ngiyakungabaza. Futhi lapho sibona ukuthi liyini izinga lokuphendula langempela, ngikholwa ukuthi sizokwazi ukwenza lokhu njalo.”
